The newly synthesized ligand and complexes have been assessed for their growth inhibiting potencies against H37Rv strain of Mycobacterium tuberculosis.
Two of the new derivatives showed 2 fold improvement of growth inhibiting potency and also decreased DNMT1 protein levels in lung cancer cells.
Among them, compounds 37 and 44 exhibited excellent enzyme-inhibiting potency, comparable to that of OM99-2, and obvious inhibitory effects in cell-based assay with low molecular weights (<600).
Parameter estimates showed that chemotherapy had a greater inhibiting potency than hormonotherapy, as expected (A50c=0.0003; A50c=0.0003 A50c=0.0003c).
Taken together, these results indicate that loss of Jak2 only selectively inhibits the potency of DCs to initiate innate immune response without perceptible effect on DC-mediated adaptive immune response.
In this study, however, we found that whereas rISP2 was able to inhibit the serine peptidase activity of a sand fly midgut extract (showing 60% inhibition at 2 nM), under the same conditions rISP1 inhibited with less potency (with 40% inhibition at 6.7 µM).
Indeed, 8-aza bivalent tropanes inhibited DAT with potency about 10-fold lower (DAT: IC50 = 31 nM) than their monovalent counterparts.
When the compound was profiled against human MRC5 cell lysates, GSK3α, GSK3β, and CDK9 were inhibited with nanomolar potency.
SERT was inhibited at lower potency, and, again, GAT1 was completely unaffected, a pattern seen with mephedrone.
The kinobead profiling of DDD85893 against T. brucei cell lysates confirmed that TbGSK3 was inhibited with nanomolar potency, with three other CMGC kinases inhibited at micromolar level.
